New market study, "Cambodia Pharmaceuticals & Healthcare Report Q3 2016", has been published

Cambodia's pharmaceutical market will remain favourable for low-cost generic drugs. This is due to the low per-capita pharmaceutical and healthcare spending in the country as well as the growing chronic disease burden in the country, which will drive up demand for treatments. Firms seeking to leverage opportunities in Cambodia will face competition from traditional medicines, which remain entrenched in the country.Headline Expenditure ProjectionsPharmaceuticals: KHR1,008.1bn (USD250mn) in 2015 to KHR1,113.5bn (USD280mn) in 2016; +10.5% in local currency terms and US dollar terms. Forecast remains unchanged from previous quarter.
Healthcare: KHR3,981.1bn (USD1.0bn) in 2015 to KHR4,181.1bn (USD1.1bn) in 2016; +5.0% in local currency terms and US dollar terms. Forecast downgraded from previous quarter.Risk/Reward IndexCambodia's Pharmaceutical Risk/Reward Index score for Q316 is 32.9 out of the maximum 100. The country scored below average for almost all indicators and sub-indicators including overall market expenditure, sector value growth and pensionable population. Consequently, with this low score, Cambodia ranks second-to-last out of the 19 key markets in Asia Pacific, ahead of Myanmar. Cambodia mainly suffers from low per capita consumption, stemming from low wages, the absence of a national health insurance scheme and the wider lack of government financing in the country, poor intellectual property protection and cumbersome bureaucracy.Latest UpdatesIn April 2016, the World Bank stated that 100% of Cambodia's poor are covered by the Health Equity Fund and that more babies are being delivered by health professionals in the country.In the same month, according to local media outlet The Phnom Penh Post, approximately 360,000 workers in various parts of the country will get access to health care coverage from May 1 due to the expansion of the National Social Security Fund.In March 2016, CEO of GlaxoSmithKline, Sir Andrew Witty announced that the company would not file for patents for new medicines in poor countries such as Cambodia.BMI Economic ViewThe Cambodian government is looking to improve regulation in order to attract more investment into the country's casino industry. An expanded casino industry would help the Cambodian government achieve its goal of boosting Chinese tourist arrivals over the coming years.BMI Political ViewCambodia will continue to strengthen economic and military ties with China as the former looks to secure economic and military assistance and the latter seeks closer ties with its ASEAN allies amid ongoing disputes in the South China Sea.

Full Report Details at
- http://www.fastmr.com/prod/1172850_cambodia_pharmaceuticals.aspx?afid=301

The Cambodia Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Brazil Pharmaceuticals & Healthcare Report Q3 2016
- Czech Republic Pharmaceuticals & Healthcare Report Q3 2016
- Bahrain Pharmaceuticals & Healthcare Report Q3 2016
- China Pharmaceuticals & Healthcare Report Q3 2016
- Egypt Pharmaceuticals & Healthcare Report Q3 2016